EPISODE · Apr 30, 2012 · 7 MIN
A New Day Dawning for Hodgkin Lymphoma?
from Journal of Clinical Oncology (JCO) Podcast
This podcast describes a phase 2 trial brentuximab vedotin in patients with Hodgkin lymphoma that has recurred after autologous hematopoietic stem cell transplantation. The podcast discusses the rationale for the trial, response to therapy, and associated toxicities. Future application of brentuximab vedotin to CD30+ malignancies is considered as well.
NOW PLAYING
A New Day Dawning for Hodgkin Lymphoma?
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m